Merck Makes Its Debut In Pain With Pioneering New Analgesic Class
Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.
You may also be interested in...
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
Solid Phase II efficacy data for Vertex’s pain product have brought it blinking into the light. Analysts are hoping it will lead to an additional revenue stream for Vertex behind its all-conquering cystic fibrosis franchise.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.